key: cord-0767178-dpble2jd
authors: Gao, Jia; Zhang, Liang; Liu, Xiaodan; Li, Fudong; Ma, Rongsheng; Zhu, Zhongliang; Zhang, Jiahai; Wu, Jihui; Shi, Yunyu; Pan, Yueyin; Ge, Yushu; Ruan, Ke
title: Repurposing low–molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2
date: 2020-05-14
journal: bioRxiv
DOI: 10.1101/2020.05.05.079848
sha: bf42a27399c98d8e6588694d9f31ecc3337dbd10
doc_id: 767178
cord_uid: dpble2jd

The coronavirus disease (COVID-19) pandemic caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global healthcare system. Drug repurposing is a feasible method for emergency treatment. As low–molecular-weight drugs have high potential to completely match interactions with essential SARS-CoV-2 targets, we propose a strategy to identify such drugs using the fragment-based approach. Herein, using ligand- and protein-observed fragment screening approaches, we identified niacin and hit 1 binding to the catalytic pocket of the main protease of the SARS-CoV-2 (Mpro), thereby modestly inhibiting the enzymatic activity of Mpro. Chemical shift perturbations induced by niacin and hit 1 indicate a partial overlap of their binding sites, i.e., the catalytic pocket of Mpro may accommodate derivatives with large molecular sizes. Therefore, we searched for drugs containing niacin or hit 1 pharmacophores and identified carmofur, bendamustine, triclabendazole, and emedastine; these drugs are highly capable of inhibiting protease activity. Our study demonstrates that the fragment-based approach is a feasible strategy for identifying low–molecular-weight drugs against the SARS-CoV-2 and other potential targets lacking specific drugs.

The coronavirus disease pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1-3 has so far affected >4 million people worldwide, with a mortality rate of approximately 7%. Main protease (M pro or 3CL pro ) is one of the most extensively studied targets of coronaviruses 4 . M pro plays an essential role in the cleavage of viral RNA-translated virus polypeptide 5 and recognizes at least 11 cleavage sites in replicase polyprotein 1ab, e.g., LQSAG (denotes the cleavage site). Covalent inhibitors against the SARS-CoV-2 M pro have recently demonstrated potency toward inhibiting viral replication in cellular assays 6, 7 ; this further underpins the druggability of M pro . However, these compounds remain in the early stages of preclinical studies, and the development of new drugs usually takes years. The lack of drugs targeting the SARS-CoV-2currently poses a threat to numerous COVID-19 patients.

The COVID-19 pandemic has implored the repurposing of oral drugs 8 . As most recently approved drugs have been designed and optimized for specific targets, they are unlikely to completely match interactions with the SARS-CoV-2 targets. Compared with 13550 potential drugs in the DrugBank database at various stages from preclinical studies through approval, the estimated number of drug-like compounds (molecular weight of ~500 Da) is reportedly approximately 10 60 . Therefore, the possibility of uncovering a highly potent and specific drug against the SARS-CoV-2 is quite slim. Conversely, low-molecular-weight drugs with intermediate potency and high safety can be an alternative treatment against the SARS-CoV-2. The toxicity of many low-molecular-weight drugs has been well understood owing to long clinical trials.

Furthermore, their low structural complexity adds odds to fully match the interactions with anti-SARS-CoV-2 targets; e.g., the chemical space of compounds with <11 non-hydrogen atoms is approximately 10 9 . This is the cornerstoneof fragment-based lead discovery 9 , and many of the compounds in the fragment library were indeed extracted from pharmacophores of the approved drugs. We therefore hypothesize that it is highly possible to identify a low-molecular-weight drug containing pharmacophores using fragment-based screening (FBS).

We therefore assessed 38 compounds, which are pharmacophores (substructures) of repurposing drugs proposed from virtual screening, from our fragment library 10-15 against the SARS-CoV-2 target. As these candidates have been predicted to bind at a high affinity, their pharmacophores should bind as well, albeit at a weaker affinity. These weak binders can be readily identified using a nuclear magnetic resonance (NMR) fragment-based approach, thereby eliminating the distracting false positives in virtual screening. Using our NMR fragment-based approach 16 19 , as these two proteins share 96% sequence identity. Key residues proximal to the catalytic site, including H41, V42, D48, N51,G143, H163, and V186, were thus assigned ( Figure S1 ).

Both niacin and hit 1 perturb a common residue V42, suggesting that these two hits bind to the catalytic core of SARS-CoV-2 M pro . Interestingly, these two hits also recognize different sets of residues in the catalytic core; for example, niacin perturbs H41, G143, N51, and V186 (Figure 2a) , whereas hit 1 induces CSPs of residues M165, E166, and L167 (Figure 2b ). Mapping of these residues to the surface representation of the crystal structure of the SARS-CoV-2 M pro (PDB code:

6LU7) 6 suggested that these two hits adopted different orientations in the catalytic site, with a shared anchor point near V42 (Figure 2c ). Considering the molecular size of niacin and the spatial distribution of the perturbed residues, niacin probably binds more than one site. Nevertheless, the CSP pattern suggests that the catalytic core of the SARS-CoV-2 M pro accommodates compounds larger than niacin and hit 1.

We therefore searched for low-molecular-weight (<400 Da) drugs containing the pharmacophores of niacin and hit 1. Molecular docking identified carmofur as a niacin derivative.

Titration of carmofur with 15 N-labeled SARS-CoV-2 M pro -N induced an extra setof cross peaks at a ligand:protein molar ratio of 2:1, and some original signals completely disappeared at a molar ratio of 4:1 ( Figure S2a ). This indicated a strong binding between carmofur and SARS-CoV-2 M pro , as confirmed by the IC 50 of 2.8 ± 0.2 µM determined using enzymatic assay at an M pro concentration of 0.5 µM ( Figure S2b ). However, the original NMR signals completely disappeared at a ligand:protein molar ratio that significantly deviated from a stoichiometry of 1:1. It has been recently demonstrated that carmofur is a covalent inhibitor of the main protease of theSARS-CoV-2, with an IC 50 value of 1.82 μM in the presence of 0.2 µM enzyme 6 ; this was consistent with our measurement as a higher M pro concentration was used in our case.

Collectively, these data suggest that covalent linking to the SARS-CoV-2 M pro is driven by excess carmofur. Nevertheless, using this fragment-based approach is a feasible strategy for repurposing low-molecular-weight drugs targeting SARS-CoV-2 M pro .

Further pharmacophore identification and molecular docking nominated several low-molecular-weight analogs of hit 1, for example, triclabendazole, emedastine, and bendamustine ( Figure S3a ). The single-dose enzymatic assay showed that these three drugs had significantly higher potency than hit 1 ( Figure S3b ). We further determined the dose-dependent response of bendamustine and emedastine in the inhibition of the SARS-CoV-2 M pro activity, with IC 50 values of 26 ± 1 μM and 82 ± 7 μM (Figure 3a) . The IC 50 value of triclabendazole was roughly estimated to be 70 μM from the two-dose inhibition rates (31% and 72% inhibition at 50 μM and 100 μM triclabendazole, respectively), as limited by the low aqueous solubility of triclabendazole.

Further, bendamustine and emedastine induced significantly larger CSPs in a dose-dependent manner than hit 1 (Figure 3b ).

Taken together, our fragment-based strategy facilitates the identification of low-molecular-weight drugs against the SARS-CoV-2 M pro . First, this approachcan be readily applied to identify low-molecular-weight drugs against other SARS-CoV-2 targets (e.g., RNA-dependent RNA polymerase or the receptor-binding domain of the spike protein). Second, a combination of these low-molecular-weight drugs may be used to gain higher potency than that achieved via a single compound if their binding topologies show no evidence of steric repulsion.

Finally, although carmofur and bendamustine show higher potency than the fragment screening hits, the toxicity of anti-cancer drugs remains a challenge in their clinical applications. Conversely, triclabendazole and emedastine could be valuable in inhibiting the SARS-CoV-2 replication at the early stage. It may also serve as a starting point for the next round of pharmacophore identification. In general, our study provides new insights toward the repurposing of low-molecular-weight drugs against the SARS-CoV-2 and other potential targets lacking specific drugs. 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The New England Journal of Medicine2020

A new coronavirus associated with human respiratory disease in China

Coronavirus main proteinase (3CL(pro)) structure: Basis for design of anti-SARS drugs

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

The rise of fragment-based drug discovery

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease

Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus

Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target

Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

NMR characterization of weak interactions between RhoGDI2 and fragment screening hits

Fluorine pseudocontact shifts used for characterizing the protein-ligand interaction mode in the limit of NMR intermediate exchange

Ligand proton pseudocontact shifts determined from paramagnetic relaxation dispersion in the limit of NMR intermediate exchange

H-1, C-13 and N-15 resonance assignments of SARS-CoV main protease N-terminal domain